基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 07-22 16:08:03

4.740

+0.060

+1.28%

最高4.830	最低4.500	成交量392.30万
今开4.550	昨收4.680	日振幅7.05%
总市值75.89亿	流通市值75.89亿	总股本16.01亿
成交额1,856万	换手率0.25%	流通股本16.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":4.74,"timestamp":1784707683008,"preClose":4.68,"halted":0,"volume":3923000,"delay":0,"changeRate":0.012820512820512928,"floatShares":1601000000,"shares":1601000000,"eps":-0.314752,"marketStatus":"未开盘","change":0.06,"latestTime":"07-22 16:08:03","open":4.55,"high":4.83,"low":4.5,"amount":18563214,"amplitude":0.070513,"askPrice":4.74,"askSize":5000,"bidPrice":4.7,"bidSize":48000,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":4.68,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.448868,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652638792?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK4023","BK1574","LU1169589451.USD","BK1161","02616","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128500850","title":"基石药业-B核心资产CS2009两项临床数据入选ESMO 2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1128500850","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128500850?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:05","pubTimestamp":1784505935,"startTime":"0","endTime":"0","summary":"2026年7月20日，基石药业-B发布自愿公告称，其核心产品CS2009在晚期非小细胞肺癌和转移性结直肠癌患者中的I/II期临床研究成果，获2026年欧洲肿瘤内科学会年会收录，并将以两场快速口头报告形式对外公布。ESMO年会将于2026年10月23日至26日在西班牙马德里举行。基石药业-B表示，届时将公布截至会前最新的数据；公告中的摘要信息仅统计到2026年4月，以满足会议提交时间要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1328277881.USD","LU0051755006.USD","01177","LU1242518931.SGD","01093","LU1961090484.USD","IE00BPRC5H50.USD","02142","LU0043850808.USD","LU1226287792.SGD","LU2488822045.USD","02269","IE0008368742.USD","LU1997244956.HKD","02616","01877","01801","LU0417516902.SGD","LU0572944931.SGD","SG9999002463.SGD","LU0405327494.USD","09995","LU2476274720.SGD","LU0823426480.USD","KURE","LU1226288253.USD","LU1960683339.HKD","LU0314109678.HKD","KCE","159992","09688","BK1161","LU1152091168.USD","06978","MEDX","LU0359201612.USD","LU2039709279.SGD","06185","06030","09926","BK1610","LU0979878070.USD","IBBQ","HK0000165453.HKD","600030","BK1500","LU0327786744.USD","LU2328871848.SGD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","IE00B5MMRT66.SGD","LU1226288170.HKD","LU0348825331.USD","BD","LU2488822045.USD","BK1515","09926","06185","KURE","LU1961090484.USD","MEDX","01877","06160","BK1161","LU0501845795.SGD","LU2242644610.SGD","LU1993786604.SGD","IE00B0JY6N72.USD","LU1688375341.USD","LU0456846285.SGD","LU1969619763.USD","06978","09995","LU2097828631.EUR","LU1813983027.USD","01093","02142","159992","LU0359201612.USD","LU0067412154.USD","IE0008368742.USD","02616","IBBQ","LU0348784397.USD","LU0359202008.SGD","LU0051755006.USD","LU0516422366.SGD","09688","LU0455707207.USD","LU1807302812.USD","LU0348735423.USD","601066","01801","02269","BK1588","IE0008369823.USD","LU2097828474.EUR","LU1960683339.HKD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118022467","title":"基石药业-B更新6月股份变动月报表，已发行股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118022467","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118022467?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:43","pubTimestamp":1783421001,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年7月7日公布了截至2026年6月30日的证券变动月报，显示公司当月无新增股份发行或注销，已发行及注册股本均保持不变。报告期内，公司已发行普通股总数为1,600,749,183股，库存股份数为0股，继续满足香港联合交易所有限公司的公众持股量要求。根据公告，基石药业-B法定/注册股本为2,000,000,000股普通股，每股面值USD 0.0001，法定/注册股本总额USD 200,000，与上月底保持一致。本次公告由公司董事李伟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU0456846285.SGD","LU0856984785.SGD","LU2476274308.USD","01177","LU1242518931.SGD","01093","IE00B031HY20.USD","LU1961090484.USD","LU2097828714.EUR","02142","LU1969619763.USD","BK1589","LU0043850808.USD","LU0315179316.USD","LU1226287792.SGD","LU0501845795.SGD","LU2488822045.USD","02269","IE00B5MMRT66.SGD","LU0502904849.HKD","02616","LU0417516738.SGD","01877","01801","LU0417516902.SGD","LU2097828631.EUR","LU0072913022.USD","09995","601066","LU2476274720.SGD","01477","LU1688375341.USD","159992","09688","LU3063872942.SGD","06978","LU2039709279.SGD","06185","LU0348766576.USD","09926","SG9999004220.SGD","IE0008369823.USD","LU0979878070.USD","HK0000165453.HKD","LU0516422366.SGD","LU1226287875.USD","LU2097828805.USD","LU0067412154.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01440","01021","02672","02726","BK4588","01651","00863","BK4585","06938","03310","02272","01956","02616","06675","00376","01236","01511","02696","03388","09637","01392","02142","00600","06636","07666","01866","02670","01081","07688","01609","02553","03661","00100","02632","01191","03277","02723","07630","01879","00412","01779","00068","02729","01286","02335","06872","06656","01133","02526","06658","06106","01672","03887","03355","03625","09630","00340"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1145522526","title":"基石药业-B回购42.10万股，耗资约185.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145522526","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145522526?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:32","pubTimestamp":1782743539,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月29日公告称，公司于2026年6月26日在香港联交所场内回购42.10万股股份，占当日已发行股份总数约0.0263%，回购价格介乎每股4.37港元至4.41港元，合计涉资约185.33万港元。公司表示，回购完成后已发行股份总数维持1,600,749,183股。\n公司同时披露，2026年6月23日股东通过购回授权，允许回购合计159,741,318股。截至公告日，公司已根据该授权累计购回1,261,000股，占授权通过时公司已发行股本的0.0788%。公司确认本次回购事宜严格遵守香港联交所证券上市规则及相关法例，公告由董事李伟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B回购42.10万股，耗资约185.33万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370958","title":"基石药业-B(02616.HK)6月26日斥资185.33万港元回购42.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647370958?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:28","pubTimestamp":1782743333,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647342911","title":"基石药业-B早盘涨超6% 近日与Arrotex就舒格利单抗在澳大利亚和纽西兰达成独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2647342911","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647342911?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:05","pubTimestamp":1782698700,"startTime":"0","endTime":"0","summary":"　　近日，基石药业-B发布公告，与澳大利亚领先的综合性医药健康集团DBG Health旗下核心医药商业化平台Arrotex Pharmaceuticals Pty Ltd就舒格利单抗在澳大利亚和纽西兰达成独家商业化合作。基石药业将负责向Arrotex供应舒格利单抗，并获得授权区域内收益分成。Arrotex将负责舒格利单抗在授权区域的注册申报及商业化推广工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-29/doc-iniezsvh7114365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647046344","title":"港股异动 | 基石药业-B(02616.HK)涨超5% 近日与Arrotex就舒格利单抗在澳大利亚和纽西兰达成独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2647046344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647046344?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:44","pubTimestamp":1782697489,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368329","title":"基石药业-B(02616.HK)6月25日斥资185.33万港元回购42.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646368329?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:29","pubTimestamp":1782480581,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368324","title":"基石药业-B(02616)6月25日斥资185.33万港元回购42.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368324","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646368324?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:29","pubTimestamp":1782480581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，该公司于2026年6月25日斥资185.33万港元回购42.1万股股份，每股回购价格为4.37-4.41港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194604899","title":"基石药业-B多日累计回购459.70万股，耗资约2135.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194604899","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194604899?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:26","pubTimestamp":1782480415,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月26日发布翌日披露报表，公告显示，公司于2026年6月15日至6月26日期间多次在香港联交所回购股票，合计回购4,597,000股，占相关事件前已发行股份数目的约0.29%。本次回购价格区间介乎每股港币4.40元至4.80元，总耗资约2135.69万港元。另据披露，公司股东大会已于2026年6月23日通过购回授权，最高可回购159,741,318股，当前公司已在香港联交所或其他交易所合计回购1,261,000股，约占授权通过日已发行股份总数的0.0788%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B多日累计回购459.70万股，耗资约2135.69万港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368387","title":"港股公告掘金 | 科拓股份、中科闻歌等6家公司今日上市 波司登年度股东应占溢利同比上升13.7%至约39.94亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368387","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646368387?lang=zh_cn&edition=full","pubTime":"2026-06-26 08:45","pubTimestamp":1782434749,"startTime":"0","endTime":"0","summary":"重大事项：同仁堂医养(02667)6月26日至7月2日招股 拟全球发售1.08亿股H股科拓股份(02272)：香港公开发售获2115.21倍认购 国际发售获5.56倍认购中科闻歌(01956)：香港公开发售获5966.78倍认购 全球发售净筹约8.27亿港元圣邦股份(03661)：香港公开发售获251.73倍认购 国际发售获23.5倍认购领益智造(01688)：香港公开发售获96.16倍认购 全球","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","LU1675838814.USD","LU1808992512.USD","02616","BK1512","03998","BK1500","01956","BK1574","BK4585","BK4588","BK1227","IPOS","02272","BK1589","BK1502","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164321713","title":"基石药业-B：2026年6月25日回购34万股，耗资约156.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164321713","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164321713?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:16","pubTimestamp":1782396970,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月25日发布翌日披露报表，宣布当日于香港联交所场内回购340,000股普通股，占公司已发行股本约0.0212%。根据公告，每股回购价介乎4.53港元至4.60港元，涉资总额1,562,130港元。购回授权于2026年6月23日获股东大会通过，公司可根据授权回购最多159,741,318股普通股；截至目前，已于交易所累计回购840,000股，占授权通过当日已发行股本约0.0525%。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B：2026年6月25日回购34万股，耗资约156.21万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875127","title":"基石药业-B(02616.HK)与Arrotex就舒格利单抗在澳大利亚和纽西兰达成独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875127","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646875127?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:08","pubTimestamp":1782378497,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142472289","title":"基石药业-B将获Arrotex预付款、里程碑付款及利润分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1142472289","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142472289?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:04","pubTimestamp":1782378251,"startTime":"0","endTime":"0","summary":"基石药业-B宣布，将从Arrotex获得一笔预付款、后续的里程碑付款以及产品利润分成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141838862","title":"基石药业与Arrotex就舒格利单抗在澳新市场达成独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1141838862","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141838862?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:01","pubTimestamp":1782378079,"startTime":"0","endTime":"0","summary":"基石药业-B宣布，已与澳大利亚公司Arrotex就舒格利单抗在澳大利亚和新西兰市场的独家商业化权利达成协议。根据协议条款，基石药业将获得预付款、里程碑付款以及基于产品净销售额的分级特许权使用费。Arrotex将负责该药物在澳新地区的所有商业化活动，包括注册申请、市场推广及销售。该协议的达成标志着基石药业在拓展其全球商业化版图方面迈出了重要一步，有望通过合作伙伴的本地专业能力加速产品在海外市场的准入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","06978","BD","SG9999002562.SGD","BK1574","02142","LU1242518857.USD","LU1328277881.USD","IE00BZ08YT58.USD","LU1794554557.SGD","BK0028","IE00B5MMRT66.SGD","IE00B0JY6N72.USD","06185","SG9999002463.SGD","09926","LU1813983027.USD","06160","LU0405327148.USD","LU2289578879.USD","09688","LU2097828474.EUR","01093","BK1610","01177","LU0856984785.SGD","BK0196","159992","LU0823426480.USD","LU1064130708.USD","LU0181495838.USD","LU1997245094.SGD","LU0327786744.USD","LU0348767384.USD","01877","LU0359202008.SGD","SG9999004220.SGD","LU0501845795.SGD","02269","LU1960683339.HKD","LU1226288253.USD","06030","LU2328871848.SGD","IE0008368742.USD","09995","LU2039709279.SGD","02616","IE00B031HY20.USD","LU0540923850.HKD","600030"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.0832},{"period":"1month","weight":0.0085},{"period":"3month","weight":-0.526},{"period":"6month","weight":-0.1611},{"period":"1year","weight":-0.315},{"period":"ytd","weight":-0.1006}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.030763},{"month":7,"riseRate":0.625,"avgChangeRate":0.050137},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}